36 reports of this reaction
1.8% of all CARBOPROST TROMETHAMINE reports
#14 most reported adverse reaction
GASTROINTESTINAL DISORDER is the #14 most commonly reported adverse reaction for CARBOPROST TROMETHAMINE, manufactured by Pharmacia & Upjohn Company LLC. There are 36 FDA adverse event reports linking CARBOPROST TROMETHAMINE to GASTROINTESTINAL DISORDER. This represents approximately 1.8% of all 2,057 adverse event reports for this drug.
Patients taking CARBOPROST TROMETHAMINE who experience gastrointestinal disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROINTESTINAL DISORDER is a less commonly reported adverse event for CARBOPROST TROMETHAMINE, but still significant enough to appear in the safety profile.
In addition to gastrointestinal disorder, the following adverse reactions have been reported for CARBOPROST TROMETHAMINE:
The following drugs have also been linked to gastrointestinal disorder in FDA adverse event reports:
GASTROINTESTINAL DISORDER has been reported as an adverse event in 36 FDA reports for CARBOPROST TROMETHAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROINTESTINAL DISORDER accounts for approximately 1.8% of all adverse event reports for CARBOPROST TROMETHAMINE, making it a notable side effect.
If you experience gastrointestinal disorder while taking CARBOPROST TROMETHAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.